In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates by Christina A. Sutherland et al.
Sutherland et al. Ann Clin Microbiol Antimicrob  (2016) 15:39 
DOI 10.1186/s12941-016-0155-z
RESEARCH
In vitro potency of amikacin 
and comparators against E. coli, K. pneumoniae 
and P. aeruginosa respiratory and blood isolates
Christina A. Sutherland1, Jamie E. Verastegui1 and David P. Nicolau1,2*
Abstract 
Background: The purpose of this study was to define the potency of amikacin and comparator agents against a col-
lection of blood and respiratory nosocomial isolates implicated in ICU based pulmonary infections gathered from US 
hospitals.
Methods: Minimum inhibitory concentrations of amikacin, aztreonam, cefepime, ceftazidime, ceftolozane/tazo-
bactam, ceftriaxone, ciprofloxacin, imipenem, meropenem, piperacillin/tazobactam and tobramycin were tested 
against 2460 Gram-negative isolates. Amikacin had 96 % susceptibility against the combined E. coli and K. pneumoniae 
isolates and 95 % susceptibility against P. aeruginosa.
Results: Ninety-six percent of all of isolates tested were susceptible (i.e., MICs ≤16 mg/L) to amikacin by current 
laboratory standards which demonstrates a high level of activity to combat infections caused by these organisms 
including ESBL, MDR, β-lactam and fluoroquinolone resistant strains. Moreover, 99 % of all organisms had amikacin 
MICs ≤64 mg/L.
Conclusions: Overall, these data highlight the continued potency of amikacin and suggest that the achievable lung 
concentrations of approximately 5000 mg/L with the administration of the amikacin by inhalation (Amikacin Inhale, 
BAY41-6551) will exceed the MICs typically observed for P. aeruginosa, E. coli and K. pneumoniae in the hospital setting.
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Background
The management of hospital-acquired pneumonia 
(HAP) and ventilator-associated pneumonia (VAP) has 
been made increasingly difficult due to the emergence 
of resistance and the potential for reduced antibiotic 
lung penetration in the intubated patient. HAP contin-
ues to be the second most common cause of nosocomial 
infections in the United States and is associated with 
increases in hospital length of stay, healthcare costs and 
represents a major cause of mortality especially in criti-
cally ill patients [1, 2]. VAP, a subset of HAP, that occurs 
in mechanically ventilated patients more than 48 h after 
tracheal intubation and occurs in 9–40 % of mechanically 
ventilated patient’s making it among the most frequent 
infections in the ICU [1, 3].
Gram-negative bacteria are responsible for a substan-
tial proportion of HAP and VAP infections. Pseudomonas 
aeruginosa, along with the Enterobacteriacae, Escherichia 
coli and Klebsiella pneumoniae are amongst the most 
common etiological organisms representing approxi-
mately two-thirds of causative agents [4, 5]. Nosoco-
mial pneumonia caused by P. aeruginosa, E. coli and K. 
pneumoniae continues to pose significant challenges in 
US hospitals due to their prevalence and the acquisition 
of numerous antimicrobial resistance mechanisms. As 
a result, the selection of empirical antibiotic therapy in 
patients with nosocomial respiratory tract infections has 
become increasingly challenging as the number of poten-
tially effective agents has been reduced due to evolving 
resistance. Yet more challenging is delivering sufficiently 
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high antibiotic concentrations to the lung as many par-
enteral therapies have poor or variable penetration. The 
delivery of antibiotics directly to the site of infection pre-
sents a unique clinical opportunity to enhance patient 
outcomes by achieving high local concentrations that 
overcome resistance while minimizing the potential for 
toxicity associated with systemic administration.
Amikacin Inhale (BAY41-6551) is a reformulated solu-
tion of amikacin (AMK) combined with a drug-delivery 
module that is currently under phase III study as an 
adjunctive therapy for the treatment of Gram-negative 
pneumonia in intubated and mechanical ventilated 
patients. In  vitro pharmacodynamic models evaluating 
the achievable epithelial lining fluid (ELF) concentra-
tions after the administration of AMK inhalation against 
Gram-negative organisms demonstrated rapid and sus-
tainable bactericidal killing of AMK both alone and in 
combination with systemic exposures of meropenem 
when AMK MICs were ≤256  mg/L [6]. Our objec-
tive was to define the potency and MIC distribution of 
AMK against a US collection of P. aeruginosa, E. coli, K. 
pneumoniae nosocomial isolates and relate these data to 
achievable lung concentrations of the compound when 
delivered via the aerosol route.
Methods
Fifty US hospitals, 41 teaching and 9 community pro-
vided non-duplicate nosocomial blood and respiratory 
isolates of E. coli, K. pneumoniae and P. aeruginosa from 
adult inpatients. Additionally, five of these hospitals also 
provided S. maltophilia respiratory isolates. Organisms 
were identified at each participating site using the stand-
ard methods. The isolates were transferred to trypticase 
soy agar slants for shipping to the Center for Anti-Infec-
tive Research and Development, Hartford Hospital, Hart-
ford, CT, USA. Collection occurred from 2013 into 2014.
Clinical Laboratory Standards Institute (CLSI) defined 
broth microdilution methods were employed to deter-
mine minimum inhibitory concentration (MICs) for 
AMK, aztreonam (ATM), cefepime (FEP), ceftazi-
dime (CAZ), ceftolozane/tazobactam (C/T), ceftri-
axone (CRO), ciprofloxacin (CIP), imipenem (IPM), 
meropenem (MEM), piperacillin/tazobactam (TZP) and 
tobramycin (TOB) [7]. Antibiotics were purchased from 
Sigma (St. Louis, MO) except for C/T which was pro-
vided by Cubist Pharmaceuticals. Quality control was 
performed on each batch of MIC testing using E. coli 
25922 and P. aeruginosa 27853 as defined by CLSI. All 
transfer and colony counts were performed on trypti-
case soy agar plates containing 5 % blood. CLSI and FDA 
breakpoints were used to define susceptibility. For C/T 
the FDA breakpoints of 2  mg/L for Enterobacteriaceae 
and 4  mg/L for P. aeruginosa were utilized [8]. Isolates 
that were non-susceptible to AMK (i.e., ≥32  mg/L) 
by current laboratory definitions were repeated and 
confirmed.
Pseudomonas aeruginosa were identified as multidrug 
resistant (MDR) if they displayed resistance to 3 or more 
classes as represented by the following phenotypic resist-
ance profiles: CIP (MIC ≥4 mg/L), IPM (MIC ≥8 mg/L), 
CAZ (MIC ≥32 mg/L), TZP (MIC ≥128 mg/L) and TOB 
(MIC ≥16 mg/L) [9].
Escherichia coli and K. pneumoniae were tested for 
extended spectrum β-lactamases (ESBL) production if 
they had an MIC of ≥1 to 2 mg/L of the following: ATM, 
CRO or CAZ. CLSI defined ESBL confirmation studies 
were then undertaken using additional MIC testing with 
CAZ, CAZ with clavulanate, cefotaxime and cefotaxime 
with clavulanate [7].
Isolates testing non-susceptible to ertapenem, imipe-
nem, or meropenem were evaluated for carbapenemase 
production using the CarbaNP test [10].
Results
Hospitals provided nosocomial blood (n  =  1118) and 
respiratory isolates (n = 527) of E. coli (n = 811) and K. 
pneumoniae (n = 835). Demographic from these patients 
are shown in Table 1. Rank order % susceptibility for the 
Enterobacteriaceae, was as follows: AMK 96 %, IPM 96 %, 
MEM 96 %, C/T 94 %, TZP 88 %, FEP 87 %, CAZ 85 %, 
ATM 85 %, TOB 84 %, CRO 84 % and CIP 74 % (Table 2). 
For AMK 96 % of these organisms had MICs ≤16 mg/L, 
2 % 32 mg/L and 2 % ≥64 mg/L (Fig. 1). Comparing AMK 
against both FEP (n = 216) and TZP resistant (n = 191) 
isolates only 2 % of the organisms had MICs ≥128 mg/L, 
respectively. Interesting one E. coli isolate was found to 
have an AMK MIC of 65,536 mg/L. Isolates from blood 
had a slightly higher (1–7 %) susceptibility for all agents 
tested than the respiratory isolates.
Of the 1646 E. coli and K. pneumoniae collected, 173 
isolates were confirmed to be ESBL positive. Of these 
ESBL isolates, 87 % were found to have MICs ≤16 mg/L 
to AMK. When considering only the Enterobacte-
riaceae confirmed ESBL positive isolates the rank order 
susceptibility of the conventional agents was as fol-
lows: MEM 95 %, IPM 94 %, AMK 87 %, C/T 79 %, TZP 
62 %, TOB 39 %, FEP 16 %, CIP 16 %, CAZ 14 %, ATM 
9  % and CRO 5  %. For AMK 87  % of these organisms 
had MICs ≤16  mg/L, 9  % 32  mg/L and 2  % ≥64  mg/L. 
Of the total Enterobacteriaceae isolates collected three 
E. coli and 37 K. pneumoniae were carbapenemase-pro-
ducing as defined by the CarbaNP test. The susceptibil-
ity of AMK, CIP and TOB for these isolates were 53, 15 
and 10 %, respectively. All of the other agents had <9 % 
Page 3 of 7Sutherland et al. Ann Clin Microbiol Antimicrob  (2016) 15:39 
susceptibility. For AMK 53  % of these organisms had 
MICs ≤16  mg/L, 15  % 32  mg/L and 29  % 64  mg/L and 
3 % 256 mg/L.
Hospitals provided 814 nosocomial blood and res-
piratory isolates of P. aeruginosa. Rank order  % suscep-
tibility was as follows: AMK 95 %, C/T 95 %, TOB 90 %, 
CAZ 74 %, FEP 73 %, MEM 71 %, CIP 68 %, ATM 67 %, 
TZP 67  % and IPM 62  % (Table  3). For AMK 95  % of 
these organisms had MICs ≤16 mg/L, 2 % 32 mg/L, 2 % 
64 mg/L and 1 % ≥128 mg/L (Fig. 1). Comparing AMK 
against MEM resistant isolates (n = 236), 91 % of these 
organisms had MICs ≤16  mg/L, 6  % 32–64  mg/L and 
3 % ≥128 mg/L. Comparing AMK against FEP resistant 
isolates (n  =  222), 89  % of these organisms had MICs 
≤16 mg/L, 9 % 32–64 mg/L and 2 % ≥128 mg/L. Com-
paring AMK against TZP resistant isolates (n  =  267), 
91  % of these organisms had MICs ≤16  mg/L, 7  % 
32–64 mg/L and 1 % ≥128 mg/L. Like the Enterobacte-
riaceae, P. aeruginosa isolates from blood had a higher 
(3–14) % susceptibility for all agents tested than the res-
piratory isolates. The susceptibility profile of ATM, FEP, 
CAZ, IPM, MEM and TZP was 10 to 14 % higher from 
patients with blood cultures.
Fourteen percent (n = 116) of the P. aeruginosa popula-
tion was defined as MDR. In this subset of MDR isolates, 
rank order %S was as follows: AMK 87 %, C/T 78 %, TOB 
52 %, ATM 19 %, MEM 17 %, CAZ 16 %, FEP 13 %, IPM 
11 %, CIP 11 % and TZP 6 %. While the MIC90 was 32 for 
AMK, 23 % of these organisms had MICs ≤4 mg/L, 38 % 
8 mg/L, 26 % 16 mg/L 5 % 32 mg/L, 4 % 64 mg/L, 3 % 
256  mg/L and 1  % ≥512  mg/L. Of note 2 P. aeruginosa 
isolates were found to have an AMK MIC of 65,536 mg/L.
The AMK distribution for S. maltophilia (n  =  45) 
was 29 % of these organisms had MICs ≤16 mg/L, 16 % 
32 mg/L, 9 % 64, 24 % 128 mg/L, 15 % 256 mg/L and 7 % 
≥512 mg/L.
To determine if the susceptibility of these organisms 
are influenced by the source of infection and location of 
the patient, we evaluated the % susceptibility of ICU ver-
sus Non-ICU patients. The Enterobacteriaceae had no 
more than a 2  % difference in  % susceptibility between 
the ICU (n  =  539) and Non-ICU (n  =  1106) patients. 
For the P. aeruginosa, we noted differing susceptibil-
ity profiles derived from the ICU and non-ICU setting. 
The susceptibility profile of ATM, FEP, CAZ, IPM, MEM 
and TZP was 5–11 % lower from patients in the ICU. In 
contrast, ≤3  % difference in was observed between the 
potency of ICU and non-ICU P. aeruginosa for AMK, 
C/T, CIP and TOB.
Discussion
Hospital-acquired pneumonia (HAP) and ventilator-
associated pneumonia (VAP) are among the most fre-
quent nosocomial infections encountered in the ICU and 
are responsible for increases in length of stay, mortal-
ity and morbidity in critically ill patients. P. aeruginosa, 
along with the Enterobacteriacae, E. coli and K. pneumo-
nia represent a substantial proportion of HAP and VAP 
infections. The use of empirical broad spectrum antibiot-
ics for the treatment of pneumonia has led to an increase 
in antimicrobial resistance along with the development of 
multidrug resistant Gram-negative organisms.
Appropriate antibiotic exposure at the site of infec-
tion is an important component for therapy to be clini-
cally effective. Epithelial lining fluid (ELF) is considered 
to be the site of infection for pneumonia and achieving 
sufficiently high drug concentrations in ELF are criti-
cal for treating pneumonia. The rationale for inhaling 
antibiotics is to maximize drug delivery to the target 
site of infection (ELF in the case of pneumonia) and 
limit the potential for systemic side effects. The uses of 
inhaled antimicrobials have a long history in the treat-
ment of lower respiratory tract infections specifically 
in patients with cystic fibrosis [11]. Due to the increas-
ing prevalence of resistant Gram-negative organisms in 
VAP causing difficult to treat pneumonia along with the 
limited lung concentrations that can be achieved with 
standard parentally given antibiotics there has been an 
increased interest in the use of inhaled antimicrobials 
such as inhaled amikacin for respiratory tract infections 
such as in HAP and VAP [12]. In a recently published 
study, So et  al. [6] investigated the in  vitro pharma-
codynamics of human simulated ELF concentrations 
of inhaled amikacin against variety of phenotypically 
diverse susceptible and non-susceptible K. pneumoniae 
and P. aeruginosa isolates and showed rapid bacteri-
cidal activity against isolates with an amikacin MICs of 
≤256 mg/L.
Table 1 Age, hospital location and  infection site 




No. of Percentage of isolates from:








18–30 210 37 63 63 37
31–40 166 39 61 59 41
41–50 244 44 56 50 50
51–60 470 42 58 50 50
61–70 597 65 35 51 49
>70 773 34 66 43 57
Total 2460 45 55 50 50
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The high overall susceptibility profile of amikacin against 
these Gram-negative organisms of interest in our current 
study appears to represent the sustained in vitro potency 
of the compound when compared to two previously 
reported surveillance programs [13, 14]. The INFORM 
study collected 7062 clinical P. aeruginosa isolates from 
Table 2 MIC profile of AMK and comparators for isolates of E. coli and K. pneumoniae
AMK amikacin; ATM aztreonam; FEP cefepime; CAZ ceftazidime; C/T ceftolozane/tazobactam; CRO ceftriaxone, CIP ciprofloxacin; IPM imipenem; MEM meropenem; TZP 
piperacillin/tazobactam; TOB tobramycin
Isolates Antimicrobial agent Range Modal MIC50 MIC90 %S
All isolates AMK ≤0.5–>128 2 4 16 96
n = 1646 ATM ≤0.06–>64 0.06 0.125 32 85
FEP ≤0.06–>64 0.06 0.06 32 87
CAZ ≤0.06–>64 0.25 0.25 64 85
C/T ≤0.06–>64 0.25 0.25 1 94
CRO ≤0.06–>64 0.06 0.06 128 84
CIP ≤0.015–>16 0.015 0.06 32 74
IPM ≤0.06–>64 0.25 0.25 1 96
MEM ≤0.06–>64 0.06 0.06 0.06 96
TZP ≤0.25–>256 2 4 32 88
TOB ≤0.06–>64 0.5 1 16 84
ESBL+isolates AMK 0.5–>128 16 8 32 87
n = 173 ATM ≤0.06–>64 64 64 128 9
FEP ≤0.06–>64 128 128 128 16
CAZ 0.125–>64 128 64 128 14
C/T ≤0.06–>64 0.5 1 8 79
CRO ≤0.06–>64 128 128 128 5
CIP ≤0.015–>16 32 32 32 16
IPM 0.125–>64 0.25 0.25 1 94
MEM ≤0.06–>64 0.06 0.06 0.125 95
TZP 0.25–>256 4 8 256 62
TOB 0.25–>64 32 16 64 39
FEP-R isolates AMK 0.5–>64 8 8 64 79
n = 216 ATM 0.125–>64 128 64 128 6
FEP 4–>64 128 128 128 0
CAZ 0.5–>64 128 128 128 9
C/T 0.125–>64 0.5 1 128 59
CRO ≤0.06–>64 128 128 128 5
CIP ≤0.015–>16 32 32 32 13
IPM 0.06–>64 0.25 0.25 32 75
MEM ≤0.06–>64 0.06 0.06 32 75
TZP 0.25–>256 512 32 512 46
TOB 0.25–>64 32 16 64 32
TZP-R isolates AMK 0.5–>64 16 8 64 78
n = 191 ATM ≤0.06–>64 128 32 128 36
FEP ≤0.06–>64 128 16 128 39
CAZ 0.25–>64 128 64 128 33
C/T ≤0.06–>64 128 1 128 56
CRO ≤0.06–>64 128 128 128 35
CIP ≤0.015–>16 32 32 32 34
IPM 0.125–>64 0.25 0.5 32 70
MEM ≤0.06–>64 0.06 0.06 32 71
TZP 32–>256 512 256 512 0
TOB 0.025–>64 32 16 64 39
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Europe, Asia/South Pacific, Latin America and Middle 
East/Africa [13]. Similar to our data the INFORM global 
surveillance program found amikacin to have a high sus-
ceptibility (89.4 %) against the P. aeruginosa isolates tested. 
Moreover, the authors also reported similar (±6  %) sus-
ceptibility profiles for ceftazidime, cefepime, piperacillin-
tazobactam and meropenem to that in our current study.
The SMART surveillance program collected intra-
abdominal isolates of E. coli, K. pneumoniae, K. oxytoca 
and P. mirabilis [14]. E. coli (n =  434) maintained high 
susceptibilities to amikacin of >99  %, while K. pneumo-
niae (n =  231) had 93.5  %. Both organisms had ≥92  % 
susceptibility to imipenem and ertapenem. In the 
SMART program amikacin retained the highest suscepti-
bility to MDR Enterobacteriaceae of all the agents tested.
Conclusions
In this study we defined the phenotypic profile of amika-
cin against 2460 blood and respiratory nosocomial isolates 
implicated in ICU based pulmonary infections collected 
from 50 US hospitals. AMK demonstrated a high level of 
activity to combat infections caused by the Enterobacte-
riacae, E. coli and K. pneumoniae including those strains 
producing ESBLs. When considering E. coli and K. pneu-
moniae our study found amikacin to have an MIC50 and 
MIC90 of 4 and 16 mg/L, respectively. Moreover, 96 % of 
organisms had a MIC of ≤16 mg/L and nearly all (99 %) 
organisms had MICs ≤64  mg/L despite concomitant 
β-lactam or fluoroquinolone resistance. In a study con-
ducted by Sader et al. [15] analyzing the in vitro activity 
of amikacin against isolates gathered from patients hos-
pitalized with pneumonia including VAP, across 62 US 
hospitals, the MIC50 and MIC90 was reported to be 1 and 
32 mg/L, respectively, against K. pneumoniae. In a study 
investigating E. coli isolates across 66 Canadian medical 
centers the reported amikacin MIC50 and MIC90 were ≤2 
and 4 mg/L, respectively [16].
For P. aeruginosa, our study found amikacin to have an 
MIC50 and MIC90 of 8 and 16 mg/L, respectively. Against 
these isolates 95  % of organisms had amikacin MICs of 
≤16  mg/L, moreover nearly all (97  %) organisms have 
MICs ≤32  mg/L. Similarly when compared to the Sader 
et al. [15] study, P. aeruginosa isolates from 62 US hospitals, 
amikacin was reported to have an MIC50 and MIC90 of 4 
and 8 mg/L, respectively. Another study analyzing similar 
data from 127 isolates from Canadian hospitals, reported 
MIC50 and MIC90 of 4 and 16 mg/L, respectively [17].
With respect to resistant Gram-negative bacteria, our 
study demonstrated that amikacin maintained potent 
activity against P. aeruginosa MDR organisms. In regards 
to ESBLs this study showed that AMK was a potent anti-
microbial with a high level of activity against these MDR 
isolates as 87 % had an MIC of ≤16 mg/L. Against MDR 
P. aeruginosa isolates, amikacin was the most potent anti-
biotic tested as 87 % of resistant isolates were considered 
susceptible (i.e., MIC of ≤16 mg/L).
The current surveillance study which incorporated 
a large number of US hospitals demonstrated the high 
potency of amikacin against contemporary isolates of 
E. coli, K. pneumoniae, P. aeruginosa originating from a 
96.0
































Fig. 1 Distribution of Amikacin (AMK) against E. coli (EC) and K. pneumoniae (KPN) versus P. aeruginosa (PSA)
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Table 3 MIC profile of AMK and comparators for isolates of P. aeruginosa
Isolates Antimicrobial agent Range Modal MIC50 MIC90 %S
All isolates AMK ≤0.5–>64 4 8 16 95
n = 814 ATM ≤0.06–>64 4 8 32 67
FEP ≤0.06–>64 2 4 32 73
CAZ 0.125–>64 2 4 64 74
C/T ≤0.06–>64 0.5 0.5 4 95
CIP ≤0.015–>16 0.125 0.25 16 68
IPM ≤0.06–>64 1 2 16 62
MEM ≤0.06–>64 0.5 1 16 71
TZP ≤0.25–>256 8 8 256 67
TOB ≤0.06–>64 0.5 1 8 90
MDR+isolates AMK 0.5–>64 8 8 32 87
n = 116 ATM 0.25–>64 128 32 128 19
FEP 2–>64 32 32 128 13
CAZ 2–>64 128 64 128 16
C/T 0.5–>64 1 2 32 78
CIP 2–>64 32 16 32 11
IPM 0.5–>64 32 16 32 11
MEM 0.25–>64 16 16 64 17
TZP 4–>256 256 256 512 6
TOB 0.125–>64 1 4 128 52
MEM-R isolates AMK 0.5–>64 8 8 16 91
n = 236 ATM 0.25–>64 32 16 64 35
FEP 1–>64 16 16 64 42
CAZ 0.5–>64 128 16 128 47
C/T 0.25–>64 1 1 8 89
CIP 0.06–>16 32 4 32 35
IPM 0.25–>64 16 16 32 11
MEM 4–>64 16 16 32 0
TZP 4–>256 32 32 512 36
TOB ≤0.06–>64 1 1 64 74
FEP-R isolates AMK 0.5–>64 8 8 32 89
n = 222 ATM 0.25–>64 32 32 128 23
FEP 16–>64 16 32 64 0
CAZ 2–>64 128 32 128 26
C/T 0.25–>64 1 2 8 85
CIP 0.06–>16 32 4 32 39
IPM 0.5–64 16 8 32 37
MEM ≤0.06–>64 16 8 32 38
TZP 1–>256 256 128 512 20
TOB 0.25–>64 1 1 64 76
TZP-R isolates AMK 0.5–>64 8 8 16 91
n = 267 ATM 0.25–>64 32 32 128 27
FEP 1–>64 16 16 64 34
CAZ 0.5–>64 128 32 128 31
C/T 0.25–>64 1 2 8 88
CIP ≤0.015–>16 32 2 32 46
IPM 0.125–>64 32 8 32 39
MEM 0.125–>64 16 4 32 44
TZP 32–>256 32 128 512 0
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blood or respiratory source. Moreover, despite resistance 
to representative agents from the β-lactam and fluoroqui-
nolone classes, AMK maintained high susceptibility for 
all organisms. As a result of low MIC’s and high achiev-
able lung concentrations of approximately 5000  mg/L, 
Amikacin Inhale has a potential adjunctive role in the 
management of bronchopulmonary infections caused by 
P. aeruginosa, E. coli and K. pneumoniae in the intubated 
patient. While Amikacin Inhale appears to be a viable 
adjunctive therapy, patients should also receive appropri-
ate systemic antimicrobial therapy based on local suscep-
tibilities or when available the susceptibility profile of the 
patient specific isolate(s).
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Table 3 continued
Isolates Antimicrobial agent Range Modal MIC50 MIC90 %S
TOB 0.25–>64 1 1 64 78
AMK amikacin; ATM aztreonam; FEP cefepime; CAZ ceftazidime; C/T ceftolozane/tazobactam; CIP ciprofloxacin; IPM imipenem; MEM meropenem; TZP piperacillin/
tazobactam; TOB obramycin
